Market Place
Sourcing Support
2022 drug approvals: Biopharma delivered 37 new drugs
03 Jan 2023 //
FIERCE PHARMA
CTI BioPharma Presents New Anemia Benefit Data from Pacritinib Program at ASH
11 Dec 2022 //
PRNEWSWIRE
CTI Announces Presentation of Anemia Benefit Data from Pacritinib Program
21 Sep 2022 //
PRNEWSWIRE
CTI BioPharma Presents Pivotal Data from Pacritinib Program at EHA
10 Jun 2022 //
PRNEWSWIRE
NCCN Guidelines Recommend VONJO for Myeloproliferative Neoplasms
14 Apr 2022 //
PRNEWSWIRE
VONJO Approved for Myelofibrosis with Platelet Count Below 50 x 109/L
04 Mar 2022 //
BUSINESSWIRE
CTI BioPharma Announces FDA Accelerated Approval of VONJO
28 Feb 2022 //
PRNEWSWIRE
CTI BioPharma Presents Data from Pacritinib Program
11 Dec 2021 //
PRNEWSWIRE
CTI BioPharma’s PRE-VENT Trial Misses Endpoint in Severe COVID
04 Oct 2021 //
CONTRACTPHARMA
CTI BioPharma’s PRE-VENT Trial Misses Endpoint in Severe COVID
04 Oct 2021 //
CONTRACTPHARMA
CTI BioPharma’s pacritinib fails to meet primary goal in Covid study
04 Oct 2021 //
CLINICALTRIALSARENA
CTI BioPharma Announces Presentation of Data Supporting Pacritinib
07 Dec 2020 //
PRNEWSWIRE
CTI BioPharma Initiates Rolling SNDA for Pacritinib in Myelofibrosis Patients
13 Oct 2020 //
PRNEWSWIRE
CTI Biopharma Announces Initiation of Ph3 PRE-VENT Study Evaluating Pacritinib
27 Apr 2020 //
PR NEWSWIRE
CTI Biopharma Announces Initiation of Ph 3 PRE-VENT Study Evaluating Pacritinib
27 Apr 2020 //
PR NEWSWIRE
CTI BioPharma Establishes Accelerated Approval Pathway for Pacritinib
03 Feb 2020 //
PR NEWSWIRE
CTI BioPharma Begins Patient Enrollment in Pivotal Phase 3 Trial of Pacritinib
02 Oct 2019 //
BIOSPACE
Facing rejection, CTI pulls European filing for pacritinib
01 Feb 2019 //
FIERCE BIOTECH
Committee for medicinal products for human use (CHMP)
28 Jan 2019 //
EMA
CTI BioPharma Provides update after Regulatory Feedback from FDA on Pacritinib
18 Dec 2018 //
PR NEWSWIRE
CTI BioPharma Announces Update Following Type B Meeting with FDA
18 Jul 2018 //
PRNEWSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.